CN104840427A - 一种含有孟鲁司特钠的药物组合物 - Google Patents
一种含有孟鲁司特钠的药物组合物 Download PDFInfo
- Publication number
- CN104840427A CN104840427A CN201410049923.6A CN201410049923A CN104840427A CN 104840427 A CN104840427 A CN 104840427A CN 201410049923 A CN201410049923 A CN 201410049923A CN 104840427 A CN104840427 A CN 104840427A
- Authority
- CN
- China
- Prior art keywords
- menglusitena
- pharmaceutical composition
- composition containing
- gained
- granule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 24
- LBFBRXGCXUHRJY-HKHDRNBDSA-M montelukast sodium Chemical compound [Na+].CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC([O-])=O)CC1 LBFBRXGCXUHRJY-HKHDRNBDSA-M 0.000 title abstract description 9
- 229960001951 montelukast sodium Drugs 0.000 title abstract description 9
- -1 sucrose fatty acid ester Chemical class 0.000 claims abstract description 19
- 229930006000 Sucrose Natural products 0.000 claims abstract description 18
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 18
- 239000000194 fatty acid Substances 0.000 claims abstract description 18
- 229930195729 fatty acid Natural products 0.000 claims abstract description 18
- 239000005720 sucrose Substances 0.000 claims abstract description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 39
- 239000011812 mixed powder Substances 0.000 claims description 26
- 239000008187 granular material Substances 0.000 claims description 22
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 21
- 238000002360 preparation method Methods 0.000 claims description 20
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 18
- 239000012467 final product Substances 0.000 claims description 14
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 13
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 13
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 13
- 238000000227 grinding Methods 0.000 claims description 13
- 229920002472 Starch Polymers 0.000 claims description 12
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 12
- 239000008107 starch Substances 0.000 claims description 12
- 235000019698 starch Nutrition 0.000 claims description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 10
- 239000000945 filler Substances 0.000 claims description 8
- 239000000741 silica gel Substances 0.000 claims description 8
- 229910002027 silica gel Inorganic materials 0.000 claims description 8
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims description 6
- 239000000314 lubricant Substances 0.000 claims description 6
- 235000019359 magnesium stearate Nutrition 0.000 claims description 6
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 5
- 229930195725 Mannitol Natural products 0.000 claims description 5
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 5
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 5
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 5
- 238000004132 cross linking Methods 0.000 claims description 5
- 239000000594 mannitol Substances 0.000 claims description 5
- 235000010355 mannitol Nutrition 0.000 claims description 5
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 5
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 5
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 239000011734 sodium Substances 0.000 claims description 5
- 229910052708 sodium Inorganic materials 0.000 claims description 5
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 5
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
- 229920000881 Modified starch Polymers 0.000 claims description 3
- 239000008101 lactose Substances 0.000 claims description 3
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 claims description 3
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 3
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 3
- 235000000346 sugar Nutrition 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 abstract description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 abstract 2
- 239000002211 L-ascorbic acid Substances 0.000 abstract 1
- 235000000069 L-ascorbic acid Nutrition 0.000 abstract 1
- 229960005070 ascorbic acid Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000009776 industrial production Methods 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
- 239000000243 solution Substances 0.000 description 24
- 238000012360 testing method Methods 0.000 description 11
- 238000000034 method Methods 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 8
- UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 description 7
- 229960005127 montelukast Drugs 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 239000012535 impurity Substances 0.000 description 6
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 4
- 238000004811 liquid chromatography Methods 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 238000003556 assay Methods 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 238000005286 illumination Methods 0.000 description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 239000013558 reference substance Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- ZLOLVGQQYDQBMP-HKHDRNBDSA-N 2-[1-[[(1r)-1-[3-[(e)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl]-3-[2-(2-hydroxypropan-2-yl)phenyl]propyl]sulfanylmethyl]cyclopropyl]acetic acid;n-cyclohexylcyclohexanamine Chemical class C1CCCCC1NC1CCCCC1.CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 ZLOLVGQQYDQBMP-HKHDRNBDSA-N 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 238000007908 dry granulation Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000010812 external standard method Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- KVVDRQDTODKIJD-UHFFFAOYSA-N 2-cyclopropylacetic acid Chemical compound OC(=O)CC1CC1 KVVDRQDTODKIJD-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- PMZXXNPJQYDFJX-UHFFFAOYSA-N acetonitrile;2,2,2-trifluoroacetic acid Chemical compound CC#N.OC(=O)C(F)(F)F PMZXXNPJQYDFJX-UHFFFAOYSA-N 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 229940068682 chewable tablet Drugs 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- 239000012738 dissolution medium Substances 0.000 description 1
- 238000011978 dissolution method Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
Description
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410049923.6A CN104840427B (zh) | 2014-02-13 | 2014-02-13 | 一种含有孟鲁司特钠的药物组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410049923.6A CN104840427B (zh) | 2014-02-13 | 2014-02-13 | 一种含有孟鲁司特钠的药物组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104840427A true CN104840427A (zh) | 2015-08-19 |
CN104840427B CN104840427B (zh) | 2017-09-29 |
Family
ID=53840678
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410049923.6A Active CN104840427B (zh) | 2014-02-13 | 2014-02-13 | 一种含有孟鲁司特钠的药物组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104840427B (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104666266A (zh) * | 2015-03-23 | 2015-06-03 | 王菊明 | 一种含有孟鲁司特钠的固体口服制剂及其制备方法 |
WO2017038732A1 (ja) * | 2015-08-31 | 2017-03-09 | 大蔵製薬株式会社 | モンテルカストの含水医薬製剤 |
CN107693494A (zh) * | 2017-08-31 | 2018-02-16 | 山东达因海洋生物制药股份有限公司 | 一种孟鲁司特钠颗粒组合物及其制备方法 |
CN111110679A (zh) * | 2018-10-31 | 2020-05-08 | 长春海悦药业股份有限公司 | 一种含有孟鲁司特钠的药物组合物 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1575163A (zh) * | 2001-10-26 | 2005-02-02 | 麦克弗罗斯特(加拿大)公司 | 孟鲁司特颗粒制剂 |
WO2007077135A1 (en) * | 2005-12-30 | 2007-07-12 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Pharmaceutical composition containing montelukast |
WO2012064304A2 (en) * | 2010-11-11 | 2012-05-18 | Mahmut Bilgic | Combinations comprising montelukast |
CN103181885A (zh) * | 2011-12-30 | 2013-07-03 | 北京韩美药品有限公司 | 氯吡格雷的固体制剂及制备方法 |
-
2014
- 2014-02-13 CN CN201410049923.6A patent/CN104840427B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1575163A (zh) * | 2001-10-26 | 2005-02-02 | 麦克弗罗斯特(加拿大)公司 | 孟鲁司特颗粒制剂 |
WO2007077135A1 (en) * | 2005-12-30 | 2007-07-12 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Pharmaceutical composition containing montelukast |
WO2012064304A2 (en) * | 2010-11-11 | 2012-05-18 | Mahmut Bilgic | Combinations comprising montelukast |
CN103181885A (zh) * | 2011-12-30 | 2013-07-03 | 北京韩美药品有限公司 | 氯吡格雷的固体制剂及制备方法 |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104666266A (zh) * | 2015-03-23 | 2015-06-03 | 王菊明 | 一种含有孟鲁司特钠的固体口服制剂及其制备方法 |
CN104666266B (zh) * | 2015-03-23 | 2017-09-22 | 曲素欣 | 一种含有孟鲁司特钠的固体口服制剂及其制备方法 |
WO2017038732A1 (ja) * | 2015-08-31 | 2017-03-09 | 大蔵製薬株式会社 | モンテルカストの含水医薬製剤 |
CN107693494A (zh) * | 2017-08-31 | 2018-02-16 | 山东达因海洋生物制药股份有限公司 | 一种孟鲁司特钠颗粒组合物及其制备方法 |
CN107693494B (zh) * | 2017-08-31 | 2021-02-09 | 山东达因海洋生物制药股份有限公司 | 一种孟鲁司特钠颗粒组合物及其制备方法 |
CN111110679A (zh) * | 2018-10-31 | 2020-05-08 | 长春海悦药业股份有限公司 | 一种含有孟鲁司特钠的药物组合物 |
Also Published As
Publication number | Publication date |
---|---|
CN104840427B (zh) | 2017-09-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104434809A (zh) | 一种奥拉帕尼固体分散体制剂及其制备方法 | |
CN104840427A (zh) | 一种含有孟鲁司特钠的药物组合物 | |
CN102670485B (zh) | 含缬沙坦的固体组合物中水解杂质h的研究及控制方法 | |
CN103054815A (zh) | 替比培南酯口服固体制剂及其制备方法 | |
CN103127025B (zh) | 消旋2-(α-羟基戊基)苯甲酸盐片的制备方法 | |
CN103933000A (zh) | 一种阿齐沙坦片剂及其制备方法 | |
CN104473892B (zh) | 一种用于直接压片的法罗培南钠组合物及其制备方法 | |
CN103435496A (zh) | 一种盐酸溴己新化合物,其制备方法及其药物组合物和制剂 | |
CN106606494A (zh) | 一种匹莫范色林药物组合物及其制备方法 | |
CN106265557A (zh) | 含有替格瑞洛的药物组合物 | |
CN104840460B (zh) | 一种含有缬沙坦和氨氯地平的药物组合物 | |
CN102462667A (zh) | 一种硫酸氢氯吡格雷片剂 | |
CN104055741A (zh) | 一种孟鲁司特钠片剂及其制备方法 | |
CN105596341A (zh) | 一种琥珀酸曲格列汀固体制剂及制备方法 | |
CN103989680B (zh) | 一种含有匹伐他汀钙的药物组合物 | |
CN104352465B (zh) | 一种不含二氧化硅的琥珀酸普芦卡必利药物组合物及其制备方法 | |
CN103385863B (zh) | 一种薁磺酸钠缓释制剂 | |
CN103494818B (zh) | 一种烟酸辛伐他汀缓释片及其制备方法 | |
CN107982228B (zh) | 一种双氢青蒿素的片剂及其制备方法 | |
CN105769800A (zh) | 一种盐酸沙格雷酯片及其制备方法 | |
CN103961333A (zh) | 甲磺酸帕罗西汀胶囊及其制备方法 | |
CN106880617B (zh) | 一种他克莫司胶囊 | |
CN111110679A (zh) | 一种含有孟鲁司特钠的药物组合物 | |
CN105581989B (zh) | 一种含有非诺贝酸的药物组合物 | |
CN104688696B (zh) | 一种含有坎地沙坦酯的药物组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
EXSB | Decision made by sipo to initiate substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information |
Address after: 130012, 672, pioneering street, hi tech Zone, Jilin, Changchun Applicant after: CHANGCHUN HAIYUE PHARMACEUTICAL Co.,Ltd. Address before: 130012, 672, pioneering street, hi tech Zone, Jilin, Changchun Applicant before: Changchun Haiyue Pharmaceutical Co.,Ltd. |
|
COR | Change of bibliographic data | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A drug combination containing montelukast sodium Effective date of registration: 20231226 Granted publication date: 20170929 Pledgee: China Construction Bank Co.,Ltd. Changchun Science and Technology Sub branch Pledgor: CHANGCHUN HAIYUE PHARMACEUTICAL Co.,Ltd. Registration number: Y2023220000149 |